Key Highlights

  • Net loss narrowed to USD 4.7 million, or USD 1.47 per share, in the third quarter from USD 7.7 million, or USD 2.44 per share, as research spending fell to USD 1.5 million from USD 4.3 million.
  • Cash and cash equivalents were USD 20.2 million at September 30, 2026, and the filing says there is substantial doubt about the company continuing as a Going Concern within one year.
  • Pre-merger Passage Bio holders are expected to own about 6% of the combined company, with Remix holders at about 65% and concurrent financing investors at about 29%, the filing says.
  • Stockholders approved the Remix Merger and a reverse split on November 5, 2026, and the deal is expected to close in the fourth quarter, with a new name and ticker planned.

Smaller Loss as Gene Therapy Programs Wind Down

Passage Bio (NASDAQ:PASG) filed its Quarterly Report on November 10, 2026 for the period ended September 30, 2026. Research and Development expense fell USD 2.8 million, mainly on lower rent after a Lease termination and reduced headcount. General and administrative expense fell to USD 3.4 million from USD 4.3 million. For nine months, net loss was USD 20.1 million, or USD 6.26 per share, versus USD 32.5 million, or USD 10.26, helped by a USD 2.6 million net gain on lease terminations. The company cut its workforce by about 75% in April 2026 and ended agreements covering its former lead candidate PBFT02.

Remix Merger Terms and the 6% Stake for Existing Holders

The company signed a merger agreement with Remix Therapeutics on June 24, 2026, amended and restated on September 2, 2026. The pro forma split of about 65% for Remix holders, about 6% for Passage Bio holders and about 29% for financing investors assumes USD 100.0 million of concurrent financing, a USD 20.0 million valuation for the company and a USD 226.0 million Equity value for Remix. Management expects net cash of about USD 10.9 million at closing. Holders are also expected to receive contingent value rights tied to certain payments from the Gemma licenses, with periods ending in December 2027 and July 2028.

Going-Concern Warning and Conditions Still to Clear

The filing says cash of USD 20.2 million may not fund operations for 12 months and that the company has no Credit Facility or committed capital. The accumulated Deficit stands at USD 724.9 million. Stockholders approved the share issuance, a reverse split between 1-for-2 and 1-for-10, and a name change to Remix Therapeutics at a special meeting on November 5, 2026. Closing still depends on other conditions, including the concurrent financing and approval of a new Nasdaq listing application for the planned RMTX ticker. If the deal fails, the company would look to equity raises or another transaction.

Where Things Stand

Very little, about 6% of the combined company on the filing's assumptions, plus contingent value rights. Passage Bio (NASDAQ:PASG) trimmed its quarterly loss to USD 4.7 million and holds USD 20.2 million, but it has wound down its gene therapy work and flagged going-concern doubt. The deal depends on USD 100.0 million of concurrent financing and a new listing approval. The ownership split can shift with net cash at closing. Next markers are the expected fourth-quarter closing, the reverse split ratio and the first filings under the Remix name.